Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in enzyme-based solutions for pharmaceutical manufacturing, announced today that it plans to attend the 2026 BIO International Convention, scheduled for June 22–25, 2026, in San Diego, California. The event is a global gathering of biotechnology and life sciences companies, academic institutions, and industry participants covering a wide range of scientific and commercial disciplines.
Representatives of Quantumzyme will attend the conference to engage in informal networking meetings with industry participants. The company will not be presenting, exhibiting, sponsoring, or formally participating in conference programming. Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., stated, “We view the BIO International Convention as an important opportunity to connect with peers across the biotechnology and biomanufacturing ecosystem. Our attendance is focused on listening, learning, and engaging in informal discussions with industry participants as we continue to evaluate developments relevant to our technology and long-term objectives.”
Quantumzyme’s attendance is limited to observation and networking activities only, consistent with the company’s ongoing efforts to increase industry awareness and maintain dialogue with potential collaborators, technology partners, and other stakeholders. The company cautioned that there can be no assurance that discussions initiated during the conference will result in any agreements, transactions, or future business relationships. Additional information regarding the BIO International Convention is available at https://convention.bio.org.
This announcement underscores Quantumzyme’s strategy to build relationships within the biomanufacturing ecosystem as it advances its enzyme-based solutions. The company applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts aimed at enhancing efficiency, reducing waste, and supporting environmentally responsible production. By integrating computational modeling with laboratory validation, Quantumzyme seeks to deliver scalable, cost-effective biocatalysis solutions for the pharmaceutical industry.
The BIO International Convention provides a platform for Quantumzyme to engage with potential partners and stay abreast of industry trends, which is critical for a company focused on green chemistry and sustainable manufacturing. For more information and updates, visit www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
